Cardiol Therapeutics Inc. ( TSE:CRDL )is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the developing of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. The CA$138m market-cap company posted a loss in its most recent financial year of CA$37m and a latest trailing-twelve-month loss of CA$35m shrinking the gap between loss and breakeven. As path to profitability is the topic on Cardiol Therapeutics' investors mind, we've decided to gauge market sentiment. We've put together a brief outline of industry analyst expectations for the company, its year of breakeven and its implied growth rate.
Consensus from 5 of the Canadian Pharmaceuticals analysts is that Cardiol Therapeutics is on the verge of breakeven. They anticipate the company to incur a final loss in 2027, before generating positive profits of CA$15m in 2028. Therefore, the company is expected to breakeven roughly 2 years from today. How fast will the company have to grow each year in order to reach the breakeven point by 2028? Working backwards from analyst estimates, it turns out that they expect the company to grow 59% year-on-year, on average, which is extremely buoyant. If this rate turns out to be too aggressive, the company may become profitable much later than analysts predict.
Underlying developments driving Cardiol Therapeutics' growth isn't the focus of this broad overview, however, keep in mind that typically a pharma company has lumpy cash flows which are contingent on the drug and stage of product development the business is in. This means, large upcoming growth rates are not abnormal as the company is beginning to reap the benefits of earlier investments.
See our latest analysis for Cardiol Therapeutics
Before we wrap up, there's one aspect worth mentioning. Cardiol Therapeutics currently has no debt on its balance sheet, which is quite unusual for a cash-burning pharma, which typically has high debt relative to its equity. The company currently operates purely off its shareholder funding and has no debt obligation, reducing concerns around repayments and making it a less risky investment.
Next Steps:
There are too many aspects of Cardiol Therapeutics to cover in one brief article, but the key fundamentals for the company can all be found in one place – Cardiol Therapeutics' company page on Simply Wall St . We've also put together a list of pertinent factors you should further examine:
-
Historical Track Record: What has Cardiol Therapeutics' performance been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
-
Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on Cardiol Therapeutics' board and the CEO's background .
-
Other High-Performing Stocks: Are there other stocks that provide better prospects with proven track records? Explore our free list of these great stocks here .
Have feedback on this article? Concerned about the content? Get in touch
with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature.
We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.
It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
